Phase 1 N=12 A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.
Healthy Volunteers Bioavailability Study
Primary: Absolute Bioavailability — 62.1 % of bioavailability
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=795 A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
Coronary Artery Disease
Primary: Diagnostic Efficacy of Flurpiridaz F 18 PET Myocardial Perfusion Imaging (MPI) Sensitivity Versus SPECT Myocardial Perfusion Imaging Sensitivity — .719; .537 Proportion…
N/A N=9 A Comparison Between Wireless CROS and Bone-anchored Hearing Devices for Single-Sided Deafness: A Pilot Study
Unilateral Hearing Loss · Unilateral Deafness
Primary: Number of 5 Key Words Within 6 Sentence Lists Repeated Correctly in the Presence of Multitalker Noise — 5.44; 3.5; 4.75; -1.75 words
Phase 3 N=32 Effects of Intensive cART During Acute/Early HIV Infection
Acute HIV Infection
Primary: Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo…
N/A N=65 TUNE! Teaching the UK About Noise Exposure: A Pilot Study
Noise-induced Hearing Loss and Tinnitus
Primary: Reduction in Dangerous Listening Behaviour Defined as Weekly Personal Noise Exposure in dB (LEPD) — 71; 87; 84; 79 Decibels per week
Phase 3 N=194 Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Peak Inspiratory Capacity (IC) Comparison Between QVA149 and Placebo — 0.3790; 0.1769 Liters — p=<0.0001
Phase 2 N=195 Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
HIV Infections
Primary: Number of Participants Who Experienced a Safety Endpoint of Interest Attributed to ATV — 1; 4; 0; 0 participants
Phase 3 N=421 Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) — -0.17; -0.65; -0.93 percent — p=<0.001
Phase 3 N=102 A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Muscle Soreness
Primary: Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW. — 50.15; 54.83 units on a scale (NRS)
Phase 3 N=2,672 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 87.3; 91.1 percentage of participants — p=.0002
Phase 3 N=185 Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
Xerostomia · Depression · Hypertension
Primary: Dry Mouth Questionnaire (DMQ) — 3.4; 1.4 units on a scale
Phase 2 N=111 Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
Ulcerative Colitis
Primary: Clinical Response at Week 8 Based on Mayo Score — 37.5; 32.7 Percentage of responders — p=0.4062
Phase 3 N=955 Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial
Breast Augmentation · Breast Reconstruction · Breast Revision
Primary: 10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation — 22.3; 52.7; 35.0; 59.7 percentage of subjects
Phase 3 N=381 Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
Phase 1 N=38 Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
Advanced Non Small Cell Lung Cancer · Advanced (Inoperable) Non Small Cell Lung Cancer
Primary: AUC(0-72) of AZD9291 — 7403; 7345 nM*h